PL2480224T3 - Kompozycja farmaceutyczna do leczenia chorób zapalnych, w których pośredniczy mcp-1 - Google Patents

Kompozycja farmaceutyczna do leczenia chorób zapalnych, w których pośredniczy mcp-1

Info

Publication number
PL2480224T3
PL2480224T3 PL10747897T PL10747897T PL2480224T3 PL 2480224 T3 PL2480224 T3 PL 2480224T3 PL 10747897 T PL10747897 T PL 10747897T PL 10747897 T PL10747897 T PL 10747897T PL 2480224 T3 PL2480224 T3 PL 2480224T3
Authority
PL
Poland
Prior art keywords
mcp
treatment
pharmaceutical composition
inflammatory diseases
inflammatory
Prior art date
Application number
PL10747897T
Other languages
English (en)
Inventor
Angelo Guglielmotti
Beatrice Garrone
Alessandro Ble'
Giuseppe Biondi
Original Assignee
Acraf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acraf filed Critical Acraf
Publication of PL2480224T3 publication Critical patent/PL2480224T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/416—1,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
PL10747897T 2009-09-23 2010-09-03 Kompozycja farmaceutyczna do leczenia chorób zapalnych, w których pośredniczy mcp-1 PL2480224T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP09425368 2009-09-23
EP10747897.6A EP2480224B1 (en) 2009-09-23 2010-09-03 Pharmaceutical composition for the treatment of mcp-1 mediated inflammatory diseases
PCT/EP2010/062979 WO2011036047A1 (en) 2009-09-23 2010-09-03 Pharmaceutical composition for the treatment of mcp-1 mediated inflammatory diseases

Publications (1)

Publication Number Publication Date
PL2480224T3 true PL2480224T3 (pl) 2017-10-31

Family

ID=41722750

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10747897T PL2480224T3 (pl) 2009-09-23 2010-09-03 Kompozycja farmaceutyczna do leczenia chorób zapalnych, w których pośredniczy mcp-1

Country Status (26)

Country Link
US (1) US9492542B2 (pl)
EP (1) EP2480224B1 (pl)
JP (2) JP2013505278A (pl)
KR (1) KR101774402B1 (pl)
CN (1) CN102573827B (pl)
AR (1) AR078307A1 (pl)
AU (1) AU2010297405B2 (pl)
BR (1) BR112012006149A2 (pl)
CA (1) CA2760180C (pl)
CY (1) CY1119125T1 (pl)
DK (1) DK2480224T3 (pl)
EA (1) EA021485B1 (pl)
ES (1) ES2637024T3 (pl)
GE (1) GEP20146067B (pl)
HR (1) HRP20171209T1 (pl)
HU (1) HUE033102T2 (pl)
IL (1) IL218001A (pl)
LT (1) LT2480224T (pl)
MX (1) MX347957B (pl)
PL (1) PL2480224T3 (pl)
PT (1) PT2480224T (pl)
SG (2) SG10201405408YA (pl)
SI (1) SI2480224T1 (pl)
SM (1) SMT201700330T1 (pl)
UA (1) UA108742C2 (pl)
WO (1) WO2011036047A1 (pl)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA018185B1 (ru) 2008-03-07 2013-06-28 Ацьенде Кимике Рьюните Анджелини Франческо A.К.P.A.Ф. С.П.А. Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1 или cx3cr1
MX2010009625A (es) 2008-03-07 2010-09-28 Acraf Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
US8999292B2 (en) 2012-05-01 2015-04-07 Translatum Medicus Inc. Methods for treating and diagnosing blinding eye diseases
AU2019441740B2 (en) 2019-04-18 2025-12-18 Tracery Ophthalmics Inc. Detection, prediction, and classification for ocular disease
US11221321B2 (en) * 2019-05-29 2022-01-11 Imam Abdulrahman Bin Faisal University Liquid chromatographic method for the simultaneous analysis of antihypertensive and antilipidemic agents and interactions thereof
EP3990433B1 (en) 2019-06-25 2026-05-20 Translatum Medicus Inc. PROCESSES FOR THE MANUFACTURE OF 2-((1-BENZYL-1H-INDAZOL-3-YL)METHOXY)-2-METHYLPROPANOIC ACID AND ITS DERIVATIVES
JP2023082437A (ja) * 2021-12-02 2023-06-14 学校法人東京薬科大学 Ccl8による免疫細胞の動員が関与する炎症を抑制するための組成物
CN116688135B (zh) * 2023-07-28 2024-10-29 四川大学华西医院 一种骨关节炎药物治疗组合物及其制备方法和应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK356085A (da) 1984-08-06 1986-02-07 Upjohn Co Reninhaemmende peptid eller et farmaceutisk acceptabelt syreadditionssalt deraf
MY103189A (en) 1986-10-31 1993-05-29 Pfizer Nor-statine and nor-cyclostatine polypeptides
US4927807A (en) 1987-10-06 1990-05-22 Abbott Laboratories Glaucoma treatment
IT1230441B (it) 1989-02-07 1991-10-23 Acraf Eteri della serie dell'indazolo
CA2023099A1 (en) 1989-09-04 1991-03-05 Quirico Branca Amino acid derivatives
US5209933A (en) 1990-01-10 1993-05-11 Syntex (U.S.A.) Inc. Long acting calcium channel blocker composition
IE68045B1 (en) 1990-05-11 1996-05-15 Abbott Lab Renin inhibitors
TW198712B (pl) 1991-04-17 1993-01-21 Hoffmann La Roche
IT1253703B (it) * 1991-04-22 1995-08-23 Angelini Francesco Ist Ricerca Uso di acidi metossi alcanoici dell'indazolo per preparare un farmaco attivo nel trattamento di malattie autoimmunitarie
MY119161A (en) 1994-04-18 2005-04-30 Novartis Ag Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
US5994348A (en) * 1995-06-07 1999-11-30 Sanofi Pharmaceutical compositions containing irbesartan
IT1276031B1 (it) 1995-10-31 1997-10-24 Angelini Ricerche Spa Composizione farmaceutica per il trattamento delle malattie autoimmuni
SE9600120D0 (sv) 1996-01-15 1996-01-15 Astra Ab Novel medical use
IT1293795B1 (it) 1997-07-28 1999-03-10 Angelini Ricerche Spa Farmaco attivo nel ridurre la produzione di proteina mcp-1
US6268377B1 (en) 1998-09-28 2001-07-31 Merck & Co., Inc. Method for treating androgen-related conditions
GB0111077D0 (en) 2001-05-04 2001-06-27 Biochemie Gmbh Organic compounds
JP2005501815A (ja) 2001-05-14 2005-01-20 メルク エンド カムパニー インコーポレーテッド 治療方法
US20030060500A1 (en) * 2001-09-19 2003-03-27 Francois Mach Facilitating organ transplantation with statins (HMG-CoA reductase inhibitors)
US7183285B2 (en) 2004-04-29 2007-02-27 Pharmix Corp. Compositions and treatments for inhibiting kinase and/or HMG-CoA reductase
US20070060549A1 (en) 2004-08-10 2007-03-15 Friesen Albert D Combination therapies employing ace inhibitors and uses thereof for the treatment of diabetic disorders
US20060046996A1 (en) 2004-08-31 2006-03-02 Kowa Co., Ltd. Method for treating hyperlipidemia
EP1806137A4 (en) * 2004-10-29 2011-03-30 Kowa Co THERAPEUTIC AGENT FOR THE TREATMENT OF GLOMERULAR DISEASE
WO2007091338A1 (ja) 2006-02-07 2007-08-16 Mochida Pharmaceutical Co., Ltd. 脳卒中再発予防用組成物
WO2008084504A2 (en) 2007-01-12 2008-07-17 Rubicon Research Private Limited Pharmaceutical compositions of angiotensin ii receptor blockers
JP5930573B2 (ja) * 2007-03-01 2016-06-15 プロビオドルグ エージー グルタミニルシクラーゼ阻害剤の新規使用
MX2010009625A (es) 2008-03-07 2010-09-28 Acraf Derivados de 1-bencil-3-hidroximetilindazol y uso de los mismos en el tratamiento de enfermedades basadas en la expresion de mcp-1, cx3cr1 y p40.
EA018185B1 (ru) 2008-03-07 2013-06-28 Ацьенде Кимике Рьюните Анджелини Франческо A.К.P.A.Ф. С.П.А. Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1 или cx3cr1
DK2254869T3 (en) 2008-03-07 2017-09-04 Acraf 1-BENZYL-3-HYDROXYMETHYL INDAZOLE DERIVATIVES AND USE THEREOF IN THE TREATMENT OF DISEASES BASED ON THE EXPRESSION OF CX3CR1 AND P40

Also Published As

Publication number Publication date
IL218001A0 (en) 2012-04-30
US9492542B2 (en) 2016-11-15
EA201270449A1 (ru) 2012-08-30
CN102573827A (zh) 2012-07-11
SI2480224T1 (sl) 2017-10-30
WO2011036047A1 (en) 2011-03-31
SMT201700330T1 (it) 2017-09-07
BR112012006149A2 (pt) 2016-06-28
JP2013505278A (ja) 2013-02-14
SG178414A1 (en) 2012-03-29
HUE033102T2 (en) 2017-11-28
KR101774402B1 (ko) 2017-09-04
CA2760180C (en) 2017-07-25
KR20120090988A (ko) 2012-08-17
IL218001A (en) 2015-10-29
JP6122470B2 (ja) 2017-04-26
CN102573827B (zh) 2016-08-31
PT2480224T (pt) 2017-07-18
CY1119125T1 (el) 2018-02-14
MX2012003485A (es) 2012-04-19
UA108742C2 (uk) 2015-06-10
JP2016028026A (ja) 2016-02-25
ES2637024T3 (es) 2017-10-10
AU2010297405A1 (en) 2012-03-01
LT2480224T (lt) 2017-08-25
MX347957B (es) 2017-05-16
DK2480224T3 (en) 2017-09-04
US20120220636A1 (en) 2012-08-30
HRP20171209T1 (hr) 2017-10-20
AU2010297405B2 (en) 2016-05-26
EP2480224B1 (en) 2017-05-24
EP2480224A1 (en) 2012-08-01
GEP20146067B (en) 2014-03-25
AR078307A1 (es) 2011-10-26
EA021485B1 (ru) 2015-06-30
CA2760180A1 (en) 2011-03-31
SG10201405408YA (en) 2014-10-30

Similar Documents

Publication Publication Date Title
PT2448582T (pt) Compostos e composições terapêuticas
DK3097925T3 (da) Farmaceutisk sammensætning
BRPI1004940A2 (pt) composição farmacêutica
BRPI1012116A2 (pt) composição farmacêutica para o tratamento de doenças cardíacas
SMT201700095B (is) Composizioni farmaceutiche per inalazione
BRPI1012539A2 (pt) composições farmacêuticas
HUE039731T2 (hu) l,3-difenilprop-2-én-l-on-származékok alkalmazása májbetegségek kezelésére
SMT201400069B (it) Formulazione farmaceutica
BRPI1015939A2 (pt) composição farmacêutica
FR2947716B1 (fr) Implant prothetique ameliore
ITTO20110641A1 (it) Composizioni farmaceutiche e metodi di trattamento
IT1394400B1 (it) Composizioni farmaceutiche
HUE033690T2 (hu) Terápiás szer hangulatzavarokra
BR112012000831A2 (pt) compostos, composições farmacêuticas e métodos relacionados
EP2404592A4 (en) HAIR TREATMENT COMPOSITION
IL218001A0 (en) Pharmaceutical composition for the treatment of mcp-1 mediated inflammatory diseases
SMT201600041B (it) Agenti terapeutici 713
GB0700972D0 (en) Treatment of inflammatory disease
BR112012003149A2 (pt) composição farmacêutica
BR112012001340A2 (pt) composições farmacêuticas
PL2293805T3 (pl) Kompozycja do ssania, do leczenia chorób zapalnych jamy ustnej i gardłowej
PL2113254T3 (pl) Kompozycje do leczenia autoimmunologicznego stanu zapalnego
GB0720976D0 (en) Treatment of inflammatory disease
BRPI1006076A2 (pt) composicoes farmaceuticas
HUE036543T2 (hu) Terápiás szer szorongásos zavarokra